NEW YORK (GenomeWeb) – Exact Sciences and Pfizer announced today that they have entered into an agreement to copromote Exact's colorectal cancer screening test Cologuard.
Investors welcomed the news by sending Exact's shares up more than 22 percent to $61.20 in morning trading on the Nasdaq.